Remote IOP Opportunity Smartlens' electronics-free contact lens for remote intraocular pressure monitoring targets glaucoma management and reduces patient visits. Opportunity to sell to ophthalmology clinics, glaucoma centers, and large health systems looking to shift to proactive care. Propose pilots that integrate IOP data with existing EMR/EHR workflows, with clear ROI on reduced office visits and earlier treatment adjustments ahead of 2026 commercialization.

Strategic Partnerships With three complementary platforms—IOP monitoring lens, smart drug delivery, and AI-powered imaging—Smartlens offers a modular solution that can be co-developed or licensed to ophthalmic device makers and distributors. This enables channel partnerships or OEM deals to accelerate market entry and expand installed base.

Global IP Leadership Its patent protection in more than 40 countries and backing from Stanford and top VCs supports a scalable global strategy. This enables pursuing regional licensing, joint ventures, or distribution agreements in international markets with strong glaucoma prevalence, aligned to regulatory timelines.

Clinical Credibility Clinical credibility driven by the appointment of a Chief Medical Officer and recognition from Nature Medicine, Fortune, and BBC can accelerate clinician adoption and multi-site pilots. Leverage these signals in outreach to key opinion leaders, academic centers, and hospital procurement teams.

Funding and Readiness Recent funding rounds, including a $5.2M bridge in 2025 and a $6.1M Series A in 2023, demonstrate capital readiness to scale manufacturing, clinical trials, and sales operations. Plan your approach with early access programs and ROI-focused proposals to payers and health systems ahead of full commercialization in 2026, highlighting cost savings from remote monitoring and improved adherence.